MOVING SCIENCE FORWARD
MultiPark is a strategic research area funded by the Swedish Government. Building on the strong tradition of cutting-edge research on Parkinson's and Alzheimer's diseases at Lund University, our vision is to create new and innovative strategies for improved and novel treatments, disease modifications and eventually cures for neurodegenerative diseases, in order to improve the quality of life for people living and ageing with these disorders.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson’s disease. This conclusion is supported by new research from MultiPark researchers.
Oskar Hanson, researcher and Vice Coordinator at MultiPark, studies the mechanisms behind Alzheimer's disease: what are the causes of the main symptoms, and how can we at an early stage determine if bad memory is due to the onset of Alzheimer's disease? For this, he is now awarded 100,000 SEK by the Eric K. Fernström Foundation.
A few weeks ago MultiPark was informed by the Vice-Chancellor’s office that the government will keep the same funding in place for 2016 as it has been for 2015. With input from external board members, the steering group and the translational working groups, a budget is being prepared for the coming year.
A method for detecting early signs of Alzheimer’s disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the conclusion of a new Lund University study - the most thorough and extensive undertaken in the field so far.
The underlying cause of most brain diseases are yet largely unknown. The clumping together of certain proteins is, however, a well-documented key step in the degradation of brain structures in Parkinson’s disease (PD), Alzheimer’s disease (AD) and Multiple system atrophy (MSA). For example, the protein alpha-synuclein is a known culprit in PD and MSA. A recent study from Lund University shows that this protein is naturally produced in a certain type of the brain’s helper cells, namely the oligodendrocytes. Since very little is known about the role of alpha-synuclein in these glial cells, this discovery should open up new lines of research on the part they may play during in disease progression, particularly in MSA.